Kornimate/medical-research-clean huggingface dataset:
dexmedetomidine and sufentanil effect in pca on pediatric patients undergoing scoliosis surgery

Conditions: Dexmedetomidine

Summary: the primary purpose of this three-arm single center, randomized, subject and assessor blind, controlled clinical study is to evaluate the effect of dexmedetomidine on patient-controlled intravenous analgesia after pediatric scoliosis orthopedics.

the study is a single center, randomized, subject and assessor blinded, controlled clinical study. children who meet the inclusion/exclusion criteria will be evaluated. the patients will use a postoperative analgesic pump which is named as patient-control-analgesia (pca) until the end of surgery with different dose of drugs. the control group will be set as using sufentanil only (0.05ug/kg/h infusion and 0.05ug/kg bolus). the experimental group will use sufentanil combined with different doses of dexmedetomidine. low dose of dexmedetomidine pca formula is 0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion and 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus. high dose of dexmedetomidine pca formula is 0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion and 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus. then patients will be followed until they discharge. the purpose of this trial is to evaluate the effect of of dexmedetomidine on patient-controlled intravenous analgesia after pediatric scoliosis orthopedics.

Eligibility criteria:
inclusion criteria: * aged 1-14 years scheduled to receive scoliosis orthopedics under general anesthesia; * weight is ±15% of standard weight (standard weight (kg) = height (cm) -100); * informed consent signed. exclusion criteria: * allergy to dexmedetomidine; * obvious abnormalities of heart, lung, liver, renal function and endocrine function; * patients who can not cooperate with this trial.

Keywords: dexmedetomidine pediatric anesthesia patient-control analgesia scoliosis orthopedics
incidence and predictors of post-tips heart failure in patients with cirrhosis

Conditions: Liver Cirrhosis; Transjugular Intrahepatic Portosystemic Shunt (TIPS); Heart Failure

Summary: the purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.

hyperdynamic circulation is a common phenomenon in cirrhosis due to systemic and splanchnic vasodilatation, which may result cardic dysfunction and abnormal structure ,called cirrhotic cardiomyopathy(ccm). transjugular intrahepatic portosystemic shunt (tips), as a effective technique to alleviates portal hypertension in cirrhotic patients, often be used to treat with refractory ascites and variceal bleeding which endoscopy and drug therapy are ineffective. however, owing to the increased shunting of blood from the splanchnic vascular bed into the central vascular bed, tips further exacerbates the hyperdynamic circulatory state, which may lead to heart failure.yet there are no convincing research to study the incidence of heart failure in cirrhosis after transjugular intrahepatic portosystemic shunt. the purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.

Eligibility criteria:
inclusion criteria: 1. cirrhosis 2. tips is placed successfully 3. agree to participate in the trial exclusion criteria: 1. non-cirrhotic portal hypertension 2. previous tips or surgical shunt 3. medium to severe pulmonary hypertension 4. heart failure 5. end-stage renal disease requiring hemodialysis 6. respiratory failure 7. malignancies with a life expectancy of less than 6 months
a clinical study of pgn-edodm1 in people with myotonic dystrophy type 1

Conditions: Myotonic Dystrophy 1

Summary: the purpose of this study is to learn about the effects of an investigational medicine, pgn-edodm1, to see how safe and tolerable multiple administrations of pgn-edodm1 are for people with myotonic dystrophy type 1 (dm1) compared to placebo.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of dm1, as defined as having a repeat sequence in the dmpk gene with at least 100 ctg repeats * medical research council (mrc) score of ≥ grade 4- in bilateral tibialis anterior (ta) muscles (the ability to move through full range of motion and hold against at least moderate pressure from the examiner) * presence of myotonia * body mass index (bmi) of \< 32.0 kg/m\^2 exclusion criteria: * congenital dm1 * known history or presence of any clinically significant conditions that may interfere with study safety assessments * abnormal laboratory tests at screening considered clinically significant by the investigator * medications specific for the treatment of myotonia within 2 weeks prior to screening * percent predicted forced vital capacity (fvc) \<40% * use of an investigational drug, device, or product within 30 days of 5 half-lives of the study drug (whichever is longer) prior to screening note: other inclusion and exclusion criteria may apply.

Keywords: dm1 myotonic dystrophy 1 myotonic dystrophy pepgen pgn-edodm1 myotonic muscular dystrophy steinert&#39;s disease
new generation low level laser effect in myofacial pain syndrome

Conditions: Myofascial Pain Syndrome

Summary: low level laser treatments have been used to treat painful trigger points in myofascial pain syndrome (mps), but the effectiveness of the appropriate laser type and parameters is still uncertain. the aim of this study was to compare the effectiveness of different types of low level laser treatment (lllt) in reducing pain levels, changing oxygen saturation and bite force in patients with mps.

a total of 45 patients with mps were randomly divided into three groups. first group received lllt with grr laser over massater muscle region. patients in the second group were treated with nd:yag laser and the same protocol with nd:yag laser was performed in the placebo group using sham device. pain was evaluated by visual analogue scale (vas), change in oxygen concentration in the massater muscle was measured by functional near-infrared spectroscopy- fnirs and bite force was measured with flexiforce sensors before and after treatment.

Eligibility criteria:
inclusion criteria: -patients with symptoms of temporomandibular disorders and diagnosed with mps as a result of the clinical examination. exclusion criteria: * patients with internal tmj irregularities or degenerative joint changes, * patients with restricted mouth opening, deviation or deflection, * patients with systemic diseases, * pregnant women, * patients who had received mps treatment within the previous year

Keywords: low level laser therapy myofascial pain syndrome bite forces visual analogue scale gaalas laser neodymium doped yttrium aluminum garnet lasers
mk2461 phase i/ii study in patients with advanced solid tumors (mk-2461-002 am1)(completed)

Conditions: Neoplasm

Summary: the purposes of this phase i portion are; 1) to evaluate the safety and tolerability of mk2461 and 2) to determine the recommended phase 2 dose or doses of mk2461. the purpose of the phase ii portion is to evaluate the anti-tumor efficacy of mk2461.


Eligibility criteria:
inclusion criteria: * patients must be at least 18 years of age, with adequate organ function, and an ecog performance of \<2 exclusion criteria: * no chemotherapy, radiotherapy, or biological therapy with 4 weeks of study participation * patients must not have primary central nervous system tumor

Keywords: neoplasm malignant
study evaluating biomarkers in relapsed/refractory pediatric solid tumors

Conditions: Adenocarcinoma; Neoplasms

Summary: this is an open label, two-part study of temsirolimus given as a 60-minute intravenous (iv) infusion once weekly to pediatric subjects with advanced solid tumors. part 1 is an ascending-dose study to evaluate the safety of iv temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. subjects will receive iv temsirolimus once weekly until disease progression or unacceptable toxicity. (recruiting)


Eligibility criteria:
inclusion criteria: inclusion criteria: part 1 only: - subjects with a histological diagnosis of advanced cancer (solid tumors or central nervous system \[cns\] tumors) with disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available (histological confirmation waived for brain stem gliomas and optic pathway tumors) part 2 only: * subjects with histologically confirmed diagnosis of refractory or relapsed: neuroblastoma, high-grade gliomas: glioblastoma multiforme, anaplastic astrocytomas, and other high-grade gliomas (histological confirmation waived for brain stem gliomas), rhabdomyosarcoma. * measurable disease (for subjects with neuroblastoma, evaluable disease as determined by a positive metaiodobenzylguanidine (mibg) scan will also be permitted). exclusion criteria: exclusion criteria: * subjects receiving enzyme-inducing anticonvulsants. * pulmonary hypertension or pneumonitis * active infection or serious intercurrent illness * other exclusions apply

Keywords: pediatric tumors
exparel injection for postoperative orbital pain

Conditions: Pain, Postoperative

Summary: after surgery to remove the eye, either by enucleation or evisceration, patients have variable levels of pain for several postoperative days. some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale. the current operative standard is to infiltrate the eye socket with 0.5% bupivacaine during surgery leading to several hours of postoperative analgesia. in 2011, pacira pharmaceuticals released a bupivacaine liposomal injectable suspension (exparel, 1.3%) which offers sustained release of bupivacaine giving postoperative pain control for up to 72 hours. this medication has been used in numerous surgeries including inguinal hernia repair, hemorrhoidectomy, bunionectomy, breast reconstruction, and orthopedic surgery, and the literature reports improved pain control, decreased use of oral opioids, and increased patient satisfaction. there are no reports of the use of exparel in the ophthalmic literature. the investigators propose a randomized, controlled trial to compare the postoperative pain control offered by sustained release bupivacaine to that offered by standard plain bupivacaine after enucleation or evisceration.


Eligibility criteria:
inclusion criteria: 1. all patients undergoing enucleation or evisceration of the eye whose surgery is performed by the department of ophthalmology at mayo clinic rochester 2. willing and able to comprehend a numerical rating scale system and provide a score to assess pain, nausea, and satisfaction level. exclusion criteria: 1. age less than 18 years (exparel has not been tested in a pediatric population) 2. pregnant or nursing (exparel has not been tested in this patient population)

Keywords: enucleation evisceration exparel bupivacaine
left ventricular reverse remodeling evaluation after surgical correction of aortic regurgitation

Conditions: Aortic Valve Regurgitation; Mitral Valve Regurgitation; Left Ventricle Dilated; Left Atrium Dilated; Systolic Left Ventricular Heart Failure; Diastolic Heart Failure

Summary: investigators assume that surgical correction approach to functional mitral regurgitation during intervention for chronic aortic regurgitation in patients with severe enlargement of the left heart chambers influences reverse remodeling of the left ventricle (lv) in the postoperative period. it is suggested that functional mitral regurgitation (mr) provides supra-physiological left ventricle volume overload and this fact plays positive role in early-stage post-operative left ventricle volume and function recovery. lv volume, systolic and diastolic function will be monitored with echocardiography (echocg) along with life quality in patients with different grades of functional mitral regurgitation secondary to severe chronic aortic insufficiency after surgical treatment of aortic regurgitation.


Eligibility criteria:
inclusion criteria: * age over 18 years * planned primary elective surgery for chronic aortic regurgitation * presence of functional mitral regurgitation * end-diastolic volume of the left ventricle \&gt;= 250 ml exclusion criteria: * infectious endocarditis * history of myocardial infarction * indications on simultaneous myocardial revascularisation * acute aortic regurgitation of any etiology * previously diagnosed dilatation of the left ventricle, not associated with the development of aortic regurgitation * long-term persistent or permanent form of atrial fibrillation * pregnancy in the first 12 months after surgery * simultaneous participation in other studies * presence of implanted pacemakers * refusal to sign informed consent * acute coronary event diagnosed within 12 months after aortic valve surgery * indications for resynchronization therapy or permanent right ventricular pacing in the first 12 months after aortic valve surgery * re-do cardiac surgery for any reason within 12 months after aortic valve surgery

Keywords: reverse remodeling left ventricle dilatation mitral valve functional regurgitation recovery left ventricle reverse remodeling
efficacy of a novel hemostatic powder in gi bleeding

Conditions: Gastrointestinal Bleeding

Summary: hemospray™ is a new endoscopic hemostatic powder. aims of this multicenter prospective study is to determine effectiveness of hemospray™ on short and medium term in different clinical situations, predictive factors of rebleeding after hemospray™ application, and feasibility of the application of hemostatic powder in routine clinical practice studying in a large sample of patients.


Eligibility criteria:
inclusion criteria: * male or female aged 18 and over who need the use of hemospray® under their care in an emergency. * upper gastrointestinal hemorrhage. * patients who received the information note of the study and agreeing to participate (non-oral opposition gathered in the patient's medical record) non inclusion criteria: * patient under guardianship, curatorship. * pregnant woman.

Keywords: upper gastrointestinal bleeding, endoscopy, hemospray
telerehabilitation following arthroscopic rotator cuff repair

Conditions: Rotator Cuff Injuries

Summary: telerehabilitation is a form of tele-treatment in which rehabilitation services are dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information. the advantages of telerehabilitation include reducing unnecessary travel to the hospital and person to person contact while maintaining social distancing. while some of the patients are truly staying at remote areas, others are unable to manage travel in the lockdown period. telemedicine offers the opportunity to deliver rehabilitative services in the patients' home, closing geographic, physical, and motivational gaps. punctuality on either side is also assured since the travel times are saved on both the ends. the purpose of the research study is to compare two standard of care rehabilitation methods (telerehabilitation vs in-person rehabilitation) following routine rotator cuff repair. objectives include assessing range of motion and patient reported functional outcomes.


Eligibility criteria:
inclusion criteria: * scheduled to undergo rotator cuff repair * age 40-80 * ability to comply with a standardized postoperative protocol * willing and able to provide consent exclusion criteria: * pregnant patient * age \<40 years * previous shoulder surgery * unable to speak english or perform informed consent
endorectal coil magnetic resonance images (erc-mri)

Conditions: Prostatic Neoplasms

Summary: when we acquired mr images of the prostate gland using a coil (receiver antenna) inside the rectum, we can see areas with tumour in the prostate gland, and well as details of the anatomy. the coil inside the rectum changes the shape of the prostate gland. in order to use this images to help target radiation therapy to the tumour better, we need to deform the images to the original shape of the prostate gland without the coil. in this study, we will develop a way to deform the images accurately.


Eligibility criteria:
inclusion criteria: * adenocarcinoma of the prostate * patient undergoing dose escalated conformal ebrt * low or intermediate risk prognostic factors: psa \< or equa to20, gleason score \<8, t \<t3, n category 0 or x, m category 0 or x * \> or equal to 18 years of age * ecog performance status 0 or 1 exclusion criteria: * contraindications to mri * bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased precluding insertion of fiducial markers * ifb or collagen vascular disease * previous colorectal surgery * previous pelvic rt
comparison of two triple regimens for treatment and retreatment of chronic hepatitis c infection

Conditions: Hepatitis C Infection

Summary: the purpose of this observational study is to compare two approved treatment regimen(s) containing boceprevir and telaprevir, as part of standard of care for the treatment of hepatitis c.

the objective of the study is to compare the effect of adding 2 oral hepatitis c virus (hcv) protease inhibitors, telaprevir versus boceprevir, as part of current standard treatment regimen with (pegylated-interferon-alpha + ribavirin) for hcv genotype-1 infection. data will be obtained from medical records of consenting patients.

Eligibility criteria:
inclusion criteria: * age - 18-64 years * hcv genotype 1 * hcv rna \>100,000 * liver biopsy within 5 years before enrollment * absolute neutrophil count of at least 1200 per cubic millimeter * platelet count of at least 90,000 per cubic millimeter * hemoglobin level of at least 12 g per deciliter * signed informed consent and health insurance portability and accountability act (hipaa) forms exclusion criteria: * hcv genotypes other than genotype 1 * immunocompromised conditions including hiv, transplant or immunosuppressive drugs * decompensated liver disease or hepatocellular carcinoma * any other types of active cancer * active autoimmune disorders * major psychiatric disorders * active drug or alcohol use * pregnancy or lactation * patients with allergy to any of the drugs used in this study * drugs that may interact with boceprevir or telaprevir as listed in the package insert

Keywords: hepatitis c infection hepatitis c virus hcv
role of human milk bank in the protection of severe respiratory disease in very low birth weight premature infants

Conditions: Respiratory Infections

Summary: acute respiratory infections are the leading cause of hospitalization in premature infants worldwide. severity rates are particularly high in developing countries. numerous viruses can cause severe disease, but the most frequent agent of hospitalization is respiratory syncytial virus (rsv). in a recent study in argentina, 58% of rsv infected vlbw infants required hospitalization and 19% required mechanical ventilation. one every twenty infected infants died. unlike industrialized nations, vlbw infants in developing countries often lack access to prophylaxis against rsv with a commercially available monoclonal antibody (palivizumab). no vaccine or preventive intervention is available against any respiratory virus for infants younger than 6 months of age in developing countries and the public sector of most middle-income countries. the protective role of breastfeeding against respiratory infections in developing countries is well established. but while similar beneficial effects have been described for premature infants, the dropout rate for breastfeeding in families exposed to the uncertainties and stress of the early months of life in the neonatal intensive care unit is very high. the world health organization recommends the use of human milk donor banks to feed infants that cannot be breastfed by their own mothers. these banks are established with the purpose of collecting, screening, processing (including pasteurizing), testing and distributing donated human milk. the potential benefit of donated milk against acute disease elicited by rsv is unknown. the investigators propose to study the role of supplemental donated human milk in the prevention of hospitalizations caused by rsv in non-breastfeeding premature infants. since the investigators expect the benefits of breast milk to extend beyond protection against rsv, the effect of human milk against respiratory infections elicited by other viruses will also be evaluated.


Eligibility criteria:
inclusion criteria: * vlbw preterm neonates (birth weight \<1,500 g at birth; gestational age \<37 weeks) born alive at any of the two participating maternity hospitals integrating our network in argentina will be enrolled in the study after signature of informed consent. exclusion criteria: * vlbw infants older than one month of age (e.g.: transferred from another institution), or formula fed for over ten days, or with congenital heart disease, congenital anomalies of the respiratory tract (i.e.: tracheoesophageal fistula, pulmonary hypoplasia, diaphragmatic hernia), immune suppression, severe malformations affecting breathing (i.e. anencephaly) as well as infants who die prior to completion of the first questionnaire, or living more than 40 km away from the hospital will be excluded from participation. infants born from human immunodeficiency virus (hiv) positive mothers will also be excluded
construction of molecular diagnostic marker model for pancreatic cystic tumors based on pancreatic cystic fluid samples

Conditions: Pancreatic Neoplasms; DNA Methylation; Proteome

Summary: the goal of this observational study is to test in patients with cystic tumor of pancreas. the main questions it aims to answer are: screening of molecular diagnostic markers for pancreatic cystic tumors by cfdna methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy. participants will provide post-operative cyst fluid specimens.

patients with pancreatic cystic tumors were divided into control, mucinous tumor and non-mucinous tumor groups, and cfdna molecules and protein molecules that were significantly altered between different groups were found by cfdna methylation sequencing of pancreatic cystic fluid and proteomic detection techniques. multi-omics analysis was performed to construct a more efficient molecular diagnostic marker model. correlating models with pathological features to find molecular features associated with the degree of malignancy.

Eligibility criteria:
inclusion criteria: * subjects are ≥ 18 years old, regardless of gender; * preoperative imaging examination (eus, ct, mri) diagnosed cystic mass of pancreas and suspected cystic tumor; * subjects voluntarily accepted radical resection of pancreatic cystic tumors; * subjects or family members voluntarily sign the informed consent form for clinical research. exclusion criteria: * the excised sample does not contain cystic components, or the cystic fluid cannot be collected; * receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation; * receive antibiotic treatment within 1 week before operation; * subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor; * the subjects or their families refused to sign the informed consent form for clinical research.

Keywords: pancreas cystic neoplasm